Image

Breaking News

Featured image for “FDA Approves Opdualag (nivolumab and relatlimab-rmbw) Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma”
03/19/2022

FDA Approves Opdualag (nivolumab and relatlimab-rmbw) Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma

CONTACT: Samantha Guild President AIM at Melanoma Foundation 916/206-6100 SGuild@AIMatMelanoma.org March 19, 2022 (Richmond, California) Yesterday, Bristol Myers Squibb announced…
Blog - Melanoma360
, 
Breaking News
Featured image for “FDA Approves KIMMTRAK (tebentafusp-tebn) for the Treatment of Unresectable or Metastatic Uveal Melanoma”
01/26/2022

FDA Approves KIMMTRAK (tebentafusp-tebn) for the Treatment of Unresectable or Metastatic Uveal Melanoma

January 26, 2022 (Richmond, California) Earlier today, Immunocore announced that the U.S. Food and Drug Administration (FDA) has approved KIMMTRAK…
Blog - Melanoma360
, 
Breaking News
Featured image for “FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients”
12/04/2021

FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients

  December 4, 2021 (Richmond, California) Yesterday, Merck announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA”
10/07/2021

Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA

October 1, 2021 Kristi Rosa REPOST from OncLive The European Medicines Agency has validated its marketing authorization application for the…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “FDA Takes Steps Aimed at Improving Quality, Safety and Efficacy of Sunscreens”
09/24/2021

FDA Takes Steps Aimed at Improving Quality, Safety and Efficacy of Sunscreens

For Immediate Release: September 24, 2021 (repost from FDA) The U.S. Food and Drug Administration today took steps aimed at…
Blog - Melanoma360
, 
Breaking News
Featured image for “Immunotherapy treatment may be appropriate for patients with earlier stages of melanoma”
09/20/2021

Immunotherapy treatment may be appropriate for patients with earlier stages of melanoma

Source: University of Pittsburgh (September 20, 2021) An immunotherapy called pembrolizumab reduced cancer recurrence after surgery in patients with stage…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “USDA Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma”
09/20/2021

USDA Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma

09/20/2021 The application is based on Phase 2/3 RELATIVITY-047 trial, in which the relatlimab and nivolumab fixed-dose combination demonstrated a…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Adjuvant Immunotherapy Prolongs Recurrence-Free Survival in Resected Stage II B/C Melanoma”
09/18/2021

Adjuvant Immunotherapy Prolongs Recurrence-Free Survival in Resected Stage II B/C Melanoma

LUGANO, Switzerland – The first randomised phase III clinical trial in stage II melanoma has shown a 35% reduction in the…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Nouscom Begins Phase Ib Trial of Personalized Vaccine, Keytruda Combo in Melanoma, Lung Cancer”
08/25/2021

Nouscom Begins Phase Ib Trial of Personalized Vaccine, Keytruda Combo in Melanoma, Lung Cancer

August 24, 2021  Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical Centers NEW YORK – Nouscom…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma”
08/25/2021

Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma

August 24, 2021 07:00 AM Eastern Daylight Time Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
03/19/2022

FDA Approves Opdualag (nivolumab and relatlimab-rmbw) Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma

CONTACT: Samantha Guild President AIM at Melanoma Foundation 916/206-6100 SGuild@AIMatMelanoma.org March 19, 2022 (Richmond, California) Yesterday, Bristol Myers Squibb announced…
Featured image for “FDA Approves Opdualag (nivolumab and relatlimab-rmbw) Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma”
Blog - Melanoma360
 | 
Breaking News
01/26/2022

FDA Approves KIMMTRAK (tebentafusp-tebn) for the Treatment of Unresectable or Metastatic Uveal Melanoma

January 26, 2022 (Richmond, California) Earlier today, Immunocore announced that the U.S. Food and Drug Administration (FDA) has approved KIMMTRAK…
Featured image for “FDA Approves KIMMTRAK (tebentafusp-tebn) for the Treatment of Unresectable or Metastatic Uveal Melanoma”
Blog - Melanoma360
 | 
Breaking News
12/04/2021

FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients

  December 4, 2021 (Richmond, California) Yesterday, Merck announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda…
Featured image for “FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
10/07/2021

Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA

October 1, 2021 Kristi Rosa REPOST from OncLive The European Medicines Agency has validated its marketing authorization application for the…
Featured image for “Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
09/24/2021

FDA Takes Steps Aimed at Improving Quality, Safety and Efficacy of Sunscreens

For Immediate Release: September 24, 2021 (repost from FDA) The U.S. Food and Drug Administration today took steps aimed at…
Featured image for “FDA Takes Steps Aimed at Improving Quality, Safety and Efficacy of Sunscreens”
Blog - Melanoma360
 | 
Breaking News
09/20/2021

Immunotherapy treatment may be appropriate for patients with earlier stages of melanoma

Source: University of Pittsburgh (September 20, 2021) An immunotherapy called pembrolizumab reduced cancer recurrence after surgery in patients with stage…
Featured image for “Immunotherapy treatment may be appropriate for patients with earlier stages of melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
09/20/2021

USDA Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma

09/20/2021 The application is based on Phase 2/3 RELATIVITY-047 trial, in which the relatlimab and nivolumab fixed-dose combination demonstrated a…
Featured image for “USDA Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
09/18/2021

Adjuvant Immunotherapy Prolongs Recurrence-Free Survival in Resected Stage II B/C Melanoma

LUGANO, Switzerland – The first randomised phase III clinical trial in stage II melanoma has shown a 35% reduction in the…
Featured image for “Adjuvant Immunotherapy Prolongs Recurrence-Free Survival in Resected Stage II B/C Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
08/25/2021

Nouscom Begins Phase Ib Trial of Personalized Vaccine, Keytruda Combo in Melanoma, Lung Cancer

August 24, 2021  Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical Centers NEW YORK – Nouscom…
Featured image for “Nouscom Begins Phase Ib Trial of Personalized Vaccine, Keytruda Combo in Melanoma, Lung Cancer”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
08/25/2021

Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma

August 24, 2021 07:00 AM Eastern Daylight Time Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical…
Featured image for “Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research

Recent Posts

Featured image for “Navigating Melanoma Together: 2024 Podcast Wrap-Up”
Dec. 12, 2024

Navigating Melanoma Together: 2024 Podcast Wrap-Up

Featured image for “Beyond the Clinic’s New Host: Introducing Dr. Sam Siegel”
Dec. 10, 2024

Beyond the Clinic’s New Host: Introducing Dr. Sam Siegel

Featured image for “Managing Melanoma During the Holiday Season”
Dec. 09, 2024

Managing Melanoma During the Holiday Season

Featured image for “Beyond the Clinic’s New Host: Dr. Sam Siegel Brings a Fresh Voice to Survivorship”
Dec. 05, 2024

Beyond the Clinic’s New Host: Dr. Sam Siegel Brings a Fresh Voice to Survivorship

Featured image for “Receiving a Heart Increases Melanoma Risk”
Dec. 03, 2024

Receiving a Heart Increases Melanoma Risk

Filter by Tag